positive regulation of low-density lipoprotein particle receptor binding
Definition
Target type: biologicalprocess
Any process that activates or increases the frequency, rate or extent of low-density lipoprotein particle receptor binding. [GO_REF:0000059, GOC:BHF, GOC:nc, GOC:TermGenie, PMID:22848640]
Positive regulation of low-density lipoprotein particle receptor binding is a complex biological process that involves the modulation of the activity of low-density lipoprotein (LDL) receptors, key players in cholesterol homeostasis. LDL receptors are transmembrane proteins found on the surface of cells, primarily in the liver. Their primary function is to bind and internalize LDL particles, which are the major carriers of cholesterol in the blood.
The process of positive regulation of LDL receptor binding can be broadly categorized into several steps:
**1. Transcriptional Regulation:** The expression of LDL receptor genes is tightly controlled at the transcriptional level. Several transcription factors, including sterol regulatory element binding protein 2 (SREBP2), play a crucial role in regulating LDL receptor gene transcription. SREBP2 is a key regulator of cholesterol biosynthesis and uptake. When intracellular cholesterol levels are low, SREBP2 is activated and translocates to the nucleus, where it binds to the sterol regulatory element (SRE) in the LDL receptor promoter, leading to increased transcription of the LDL receptor gene.
**2. Post-translational Modifications:** After translation, LDL receptors undergo several post-translational modifications, including glycosylation and phosphorylation, which are crucial for their proper folding, trafficking, and function. These modifications can influence the stability and activity of the LDL receptor.
**3. Trafficking and Recycling:** Once synthesized, LDL receptors are transported to the cell surface, where they bind to LDL particles. This binding triggers the internalization of the LDL receptor-LDL complex via endocytosis. Inside the cell, the complex is directed to lysosomes, where the LDL particle is broken down, releasing cholesterol. The LDL receptor is then recycled back to the cell surface, ready to bind another LDL particle.
**4. Regulation by Cholesterol Levels:** The activity of the LDL receptor is tightly regulated by intracellular cholesterol levels. When cholesterol levels are high, the LDL receptor undergoes degradation, reducing the uptake of LDL particles. Conversely, when cholesterol levels are low, the LDL receptor is stabilized and its activity increases, leading to increased LDL uptake.
**5. Regulation by Other Factors:** In addition to cholesterol, other factors can also influence the activity of the LDL receptor. For example, insulin can stimulate LDL receptor activity, while inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), can inhibit LDL receptor function.
**6. Receptor Binding and Internalization:** The binding of LDL particles to the LDL receptor is highly specific and involves multiple interactions between the receptor and the apolipoprotein B-100 (apoB-100) protein that coats the LDL particle. This binding triggers the internalization of the LDL receptor-LDL complex through a process known as clathrin-mediated endocytosis.
**7. Lysosomal Degradation and Cholesterol Release:** The internalized LDL receptor-LDL complex is then transported to lysosomes, where the LDL particle is degraded, releasing cholesterol into the cytoplasm. The LDL receptor is subsequently recycled back to the cell surface, completing the cycle.
In summary, positive regulation of low-density lipoprotein particle receptor binding is a complex process involving multiple steps, including transcriptional regulation, post-translational modifications, trafficking and recycling, and regulation by cholesterol levels and other factors. This intricate regulation ensures that cells maintain appropriate levels of cholesterol, crucial for their normal function and survival.
'"
Proteins (1)
Protein | Definition | Taxonomy |
---|---|---|
Annexin A2 | An annexin A2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P07355] | Homo sapiens (human) |
Compounds (1)
Compound | Definition | Classes | Roles |
---|---|---|---|
N-(3,4-dimethylphenyl)-2-[[5-[[(4,6-dimethyl-2-pyrimidinyl)thio]methyl]-4-(2-furanylmethyl)-1,2,4-triazol-3-yl]thio]acetamide | anilide |